First Liquid Biopsy for Neurologic Diseases

18 – 30% of cases of Multiple Sclerosis, ALS, Parkinson’s Disease, and Alzheimer’s Disease are misdiagnosed.

The FBB Biomed blood test measures newly discovered ncRNA biomarkers for these neurologic diseases to increase diagnostic accuracy at the time of screening. This is the world’s first liquid biopsy for neurologic diseases.

The Challenge

Neurologic Misdiagnosis

Screening protocols for neurologic diseases – including Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), and Alzheimer’s Disease (AD) – currently rely on imprecise diagnostic methods and fail to provide a prognostic view to health outcomes.
 
Research indicates that up to a third of cases are misdiagnosed within this disease group, leading to incorrect treatment protocols and the use of wrong medications.

Our Solution

ncRNA Biomarkers

FBB Biomed’s newly discovered non-coding RNA biomarkers increase diagnostic accuracy at the time of screening by providing a molecular diagnostic for MS, ALS, PD, and AD.
 
FBB Biomed’s pre-clinical research has demonstrated significant potential for more accurate diagnosis of these diseases.

Our Product

NGS-based Blood Test

Leveraging next generation sequencing (NGS) and the latest advancements in bioinformatics, FBB Biomed’s blood test screens for our proprietary ncRNA biomarkers for MS, ALS, PD, and AD.

Our test runs on standard laboratory sequencing equipment and protocols. No new hardware or processes required.

Actionable Clinical Utility

Use Cases

Prognostic Screening

Is this patient at risk for severe neurodegeneration?

Differential Diagnosis

What category of neurologic disease does this patient have?

Patient Monitoring

How effective is the treatment I prescribed for this patient?

From the Scientific Community

What Others Say About Us